1
|
Valinezhad Sani F, Palizban A, Mosaffa F, Jamialahmadi K. Glucosamine attenuates drug resistance in Mitoxantrone-resistance breast cancer cells. J Pharm Pharmacol 2021; 73:922-927. [PMID: 33885909 DOI: 10.1093/jpp/rgaa032] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Accepted: 04/13/2021] [Indexed: 01/22/2023]
Abstract
OBJECTIVES This study was aimed at investigating the cytotoxicity and multi-drug resistance (MDR) reversal effect of Glucosamine (GlcN) on resistant BCRP-overexpressing breast cancer MCF-7/MX cells. METHODS After confirming the overexpression of BCRP, the cytotoxicity and MDR reversing potential of GlcN on MCF-7/MX mitoxantrone-resistant and MCF-7 sensitive breast cancer cells were assessed via MTT assay. The effects of GlcN on mitoxantrone accumulation were analyzed through flow cytometry. Finally, the expression of BCRP and Epithelial-Mesenchymal Transition (EMT)-related markers following the exposure to GlcN were assessed by real-time RT-PCR. KEY FINDINGS This study showed that glucosamine had an inhibitory effect on the proliferation of human breast cancer cells. The respective IC50 values for MCF-7/MX cells following exposure to mitoxantrone (MX) in the presence of GlcN (0, 0.5 and 1 mm) for 72 h were 3.61 ± 0.21, 0.598 ± 0.041 and 0.284 ± 0.016 μm, respectively. Furthermore, GlcN reduced the expression of BCRP mRNA without any significant effect on EMT-related markers in breast cancer cells. CONCLUSIONS These results proposed that glucosamine as a natural sugar could down regulate the BCRP expression and increased MX cytotoxicity in breast cancer cells.
Collapse
Affiliation(s)
- Fatemeh Valinezhad Sani
- Department of Clinical Biochemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.,Department of Laboratory Sciences, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad,Iran
| | - Abbasali Palizban
- Department of Clinical Biochemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Fatemeh Mosaffa
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad,Iran.,Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,Iran
| | - Khadijeh Jamialahmadi
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad,Iran.,Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad,Iran
| |
Collapse
|
2
|
Valinezhad Sani F, Palizban A, Mosaffa F, Jamialahmadi K. Glucosamine reverses drug resistance in MRP2 overexpressing ovarian cancer cells. Eur J Pharmacol 2019; 868:172883. [PMID: 31866406 DOI: 10.1016/j.ejphar.2019.172883] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Revised: 12/13/2019] [Accepted: 12/17/2019] [Indexed: 01/08/2023]
Abstract
Glucosamine (GlcN), a natural amino sugar in human body, was reported to exhibit anticancer activity against some tumors. In the present study, we evaluated the cytotoxicity and multi-drug resistance (MDR) reversal activity of GlcN on resistant MRP2-overexpressing ovarian cancer A2780RCIS cells. The cytotoxicity and MDR reversal activity of GlcN on cancer cells were measured by MTT assay. The effects of GlcN on MRP1 and MRP2 mRNA expression and function were evaluated by qRT-PCR and flow cytometry, respectively. The cell migration capacity of ovarian cancer cells were assessed in the presence or absence of GlcN using wound healing migration assay. Furthermore, the effects of GlcN on the mRNA expression of E-cadherin, vimentin and α-smooth muscle actin as Epithelial-Mesenchymal Transition (EMT)-related markers were evaluated by qRT-PCR. Our results indicated that glucosamine reduced the proliferation of human ovarian cancer cell lines (A2780) and its cisplatin resistant variant (A2780RCIS) in a dose-dependent manner. The IC50 values for A2780RCIS cells treated with cisplatin in the presence of different concentrations of GlcN (0, 1, 2 and 3 mM) for 72 h were 44.463 ± 1.603, 35.17 ± 0.025, 22.25 ± 0.018, 17.78 ± 0.012 μM respectively. Also GlcN decreased the expression of MRP1 and MRP2 mRNA in ovarian cancer cells. Our results further demonstrated that although GlcN had no significant effects on the expression of studied EMT-related markers in invasive A2780RCIS cells, it was able to inhibit their migration in vitro. According to these findings, GlcN could effectively enhance cisplatin cytotoxicity in resistant A2780RCIS cells.
Collapse
Affiliation(s)
- Fatemeh Valinezhad Sani
- Department of Clinical Biochemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Abbasali Palizban
- Department of Clinical Biochemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Fatemeh Mosaffa
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Biotechnology(,) School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
| | - Khadijeh Jamialahmadi
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
| |
Collapse
|
3
|
Valinezhad Sani F, Mosaffa F, Jamialahmadi K, Palizban A. Glucosamine Reverses P-Glycoprotein-Mediated Multidrug Resistance in the Daunorubicin-Resistant Human Gastric Cancer Cells. Nutr Cancer 2019; 72:522-527. [DOI: 10.1080/01635581.2019.1636102] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Fatemeh Valinezhad Sani
- Department of Clinical Biochemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Fatemeh Mosaffa
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Khadijeh Jamialahmadi
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Abbasali Palizban
- Department of Clinical Biochemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
4
|
Cheki M, Jafari S, Najafi M, Mahmoudzadeh A. Glucosamine Protects Rat Bone Marrow Cells Against Cisplatin-induced Genotoxicity and Cytotoxicity. Anticancer Agents Med Chem 2019; 19:1695-1702. [PMID: 31272360 DOI: 10.2174/1871520619666190704164126] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 05/20/2019] [Accepted: 05/21/2019] [Indexed: 12/22/2022]
Abstract
BACKGROUND AND OBJECTIVE Glucosamine is a widely prescribed dietary supplement used in the treatment of osteoarthritis. In the present study, the chemoprotectant ability of glucosamine was evaluated against cisplatin-induced genotoxicity and cytotoxicity in rat bone marrow cells. METHODS Glucosamine was orally administrated to rats at doses of 75 and 150 mg/kg body weight for seven consecutive days. On the seventh day, the rats were treated with a single injection of cisplatin (5 mg/kg, i.p.) at 1h after the last oral administration. The cisplatin antagonistic potential of glucosamine was assessed by micronucleus assay, Reactive Oxygen Species (ROS) level analysis, hematological analysis, and flow cytometry. RESULTS Glucosamine administration to cisplatin-treated rats significantly decreased the frequencies of Micronucleated Polychromatic Erythrocytes (MnPCEs) and Micronucleated Normchromatic Erythrocytes (MnNCEs), and also increased PCE/(PCE+NCE) ratio in bone marrow cells. Furthermore, treatment of rats with glucosamine before cisplatin significantly inhibited apoptosis, necrosis and ROS generation in bone marrow cells, and also increased red blood cells count in peripheral blood. CONCLUSION This study shows glucosamine to be a new effective chemoprotector against cisplatin-induced DNA damage and apoptosis in rat bone marrow cells. The results of this study may be helpful in reducing the harmful effects of cisplatin-based chemotherapy in the future.
Collapse
Affiliation(s)
- Mohsen Cheki
- Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Salman Jafari
- Department of Radiology Technology, School of Paramedicine, Hamadan University of Medical Sciences, Hamadan, Iran
| | - Masoud Najafi
- Radiology and Nuclear Medicine Department, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Aziz Mahmoudzadeh
- Department of Biosciences and Biotechnology, Malek-Ashtar University of Technology, Tehran, Iran
| |
Collapse
|
5
|
Ranjbar-Navazi Z, Eskandani M, Johari-Ahar M, Nemati A, Akbari H, Davaran S, Omidi Y. Doxorubicin-conjugated D-glucosamine- and folate- bi-functionalised InP/ZnS quantum dots for cancer cells imaging and therapy. J Drug Target 2017; 26:267-277. [PMID: 28795849 DOI: 10.1080/1061186x.2017.1365876] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Nanoscaled quantum dots (QDs), with unique optical properties have been used for the development of theranostics. Here, InP/ZnS QDs were synthesised and functionalised with folate (QD-FA), D-glucosamine (QD-GA) or both (QD-FA-GA). The bi-functionalised QDs were further conjugated with doxorubicin (QD-FA-GA-DOX). Optimum Indium to fatty acid (In:MA) ratio was 1:3.5. Transmission electron microscopy (TEM) micrographs revealed spherical morphology for the QDs (11 nm). Energy-dispersive spectroscopy (EDS) spectrum confirmed the chemical composition of the QDs. MTT analysis in the OVCAR-3 cells treated with bare QDs, QD-FA, QD-GA, QD-FA-GA and QD-FA-GA-DOX (0.2 mg/mL of QDs) after 24 h indicated low toxicity for the bare QDs and functionalised QDs (about 80-90% cell viability). QD-FA-GA-DOX nanoparticles elicited toxicity in the cells. Cellular uptake of the engineered QDs were investigated in both folate receptor (FR)-positive OVCAR-3 cells and FR-negative A549 cells using fluorescence microscopy and FACS flow cytometry. The FA-functionalised QDs showed significantly higher uptake in the FR-positive OVCAR-3 cells, nonetheless the GA-functionalised QDs resulted in an indiscriminate uptake in both cell lines. In conclusion, our findings indicated that DOX-conjugated FA-armed QDs can be used as theranostics for simultaneous imaging and therapy of cancer.
Collapse
Affiliation(s)
- Zahra Ranjbar-Navazi
- a Department of Materials Engineering , Science and Research Branch, Islamic Azad University , Tehran , Iran.,b Research Center for Pharmaceutical Nanotechnology , Biomedicine Institute, Tabriz University of Medical Sciences , Tabriz , Iran
| | - Morteza Eskandani
- b Research Center for Pharmaceutical Nanotechnology , Biomedicine Institute, Tabriz University of Medical Sciences , Tabriz , Iran
| | - Mohammad Johari-Ahar
- b Research Center for Pharmaceutical Nanotechnology , Biomedicine Institute, Tabriz University of Medical Sciences , Tabriz , Iran.,c Department of Medicinal Chemistry, School of Pharmacy , Ardabil University of Medical Sciences , Ardabil , Iran
| | - Ali Nemati
- d Department of Materials Science and Engineering , Sharif University of Technology , Tehran , Iran
| | - Hamid Akbari
- e Faculty of Pharmacy , Tehran University of Medical Sciences , Tehran , Iran
| | - Soudabeh Davaran
- b Research Center for Pharmaceutical Nanotechnology , Biomedicine Institute, Tabriz University of Medical Sciences , Tabriz , Iran
| | - Yadollah Omidi
- b Research Center for Pharmaceutical Nanotechnology , Biomedicine Institute, Tabriz University of Medical Sciences , Tabriz , Iran.,f Department of Pharmaceutics, Faculty of Pharmacy , Tabriz University of Medical Sciences , Tabriz , Iran
| |
Collapse
|
6
|
Harb OA, Elsayed WSH, Ismail EI, Toam MM, Ammar MG. Thioredoxin-Interact ing-Pro t e in [TXNIP] and Transglutaminase 2 [TGM2] Expression in Meningiomas of Different Grades and the Role of Their Expression in
Meningioma Recurrence and Prognosis. Asian Pac J Cancer Prev 2017; 18:2299-2308. [PMID: 28843270 PMCID: PMC5697495 DOI: 10.22034/apjcp.2017.18.8.2299] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Background: Meningiomas are common central nervous system (CNS) tumors that account for thirty percent of
primary intracranial tumors.. The accuracy of predicting meningioma recurrence and progression is not enough. So, there
is a real need for discovering recent factors for identification of the relapse risk, progression rates, which patients will
need aggressive treatment and predicting and improving patients’ survival. Thioredoxin-interacting-protein [TXNIP]
is an alpha-arrestin-protein family member that is mapped on chromosome 1-q21–22 and is found to participate in
cellular redox reactions regulations and control. Transglutaminase 2 (TGM2) is a transglutaminase enzyme family
member that is found in many human cells, it may act as an enzyme, a structural protein and also has multiple roles
in many cellular activities. Aim of our study: It was to explore the expression of TXNIP, TGM2 and Ki-67 using
immunohistochemistry in different pathological grades of meningiomas, and to investigate the relevance between
their expressions, clinicopathological criteria, disease recurrence and prognosis of meningioma patients. Methods: we
included 50 cases of meningioma of different pathological grades; all patients were managed according to their grade
by surgery alone, with radiotherapy or combined modalities. Sections from paraffin blocks prepared from samples of all
patients stained by TXNIP, TGM2 and Ki-67 using immunohistochemistry. Results: high expression of TXNIP in 28
out of 50 (56%) cases of meningioma of different pathological grades and was positively correlated with meningioma
lower grade, low KI labeling index (p=0.000), adequacy of resection, negatively correlated with high incidence of
recurrence after surgery and it was negatively correlated with meningioma higher pathological grades (p=0.000). We
detected high expression of TGM2 in 21 out of 50 (42%) cases of meningioma and it was positively correlated with
meningioma higher grade (p= 0.002), high KI labeling index (p=0.000), high incidence of recurrence after surgery,
progression to higher pathological grades and was negatively correlated with adequacy of resection of meningioma
(p=0.000). Conclusion: There is inverse relation between both [TXNIP and TGM2 expression in meningiomas and the
combination of decreased expression of TXNIP and increased expression of TGM2 could predict risk of meningioma
recurrence and progression in to higher pathological grades.
Collapse
Affiliation(s)
- Ola A Harb
- Pathology Department, Faculty of Medicine, Zagazig University, Egypt.
| | | | | | | | | |
Collapse
|
7
|
Molecular mechanisms and biomedical applications of glucosamine as a potential multifunctional therapeutic agent. Life Sci 2016; 152:21-9. [PMID: 27012765 DOI: 10.1016/j.lfs.2016.03.028] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Revised: 03/10/2016] [Accepted: 03/11/2016] [Indexed: 12/30/2022]
Abstract
Glucosamine and its acetylated derivative, N-acetyl glucosamine, are naturally occurring amino sugars found in human body. They are important components of glycoproteins, proteoglycans and glycosaminoglycans. Scientific studies have supported that glucosamine has the beneficial pharmacological effects to relieve osteoarthritis symptoms. Glucosamine can also be as a promising candidate for the prevention and/or treatment of some other diseases due to its anti-oxidant and anti-inflammatory activities. Most of its function is exerted by modulation of inflammatory responses especially through Nuclear Factor-κB (NF-κB) that can control inflammatory cytokine production and cell survival. In this review, we present a concise update on additional new therapeutic applications of glucosamine including treatment of cardiovascular disease, neurological deficits, skin disorders, cancer and the molecular mechanistic rationale for these uses. This article will also examine safety profile and adverse effects of glucosamine in human.
Collapse
|
8
|
Pawar S, Shevalkar G, Vavia P. Glucosamine-anchored doxorubicin-loaded targeted nano-niosomes: pharmacokinetic, toxicity and pharmacodynamic evaluation. J Drug Target 2016; 24:730-43. [PMID: 26878084 DOI: 10.3109/1061186x.2016.1154560] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND Efficacy of anticancer drug is limited due to non-selectivity and toxicities allied with the drug; therefore the heart of the present work is to formulate drug delivery systems targeted selectively towards cancer cells with minimal toxicity to normal cells. PURPOSE Targeted drug delivery system of doxorubicin (DOX)-loaded niosomes using synthesized N-lauryl glucosamine (NLG) as a targeting ligand. METHODS NLG-anchored DOX niosomes were developed using ethanol injection method. RESULTS Developed niosomes had particle size <150 nm and high entrapment efficiency ∼90%. In vivo pharmacokinetics exhibited long circulating nature of targeted niosomes with improved bioavailability, which significantly reduced CL and Vd than DOX solution and non-targeted niosomes (35 fold and 2.5 fold, respectively). Tissue-distribution study and enzymatic assays revealed higher concentration of DOX solution in heart while no toxicity to major organs with developed targeted niosomes was observed. Solid skin melanoma tumor model in mice manifested the commendable targeting potential of targeted niosomes with significant reduction in tumor volume and high % survival rate without drop in body weight in comparison with DOX solution and non-targeted niosomes of DOX. CONCLUSION The glucosamine-anchored DOX-loaded targeted niosomes showed its potential in cancer targeted drug therapy with reduced toxicity. Abbreviations ALT alanine transaminase CL clearance CPK creatinine phosphokinase DOX doxorubicin EDC.HCL ethyl carbidimide hydrochloride GLUT glucose transporter GSH glutathione S-transferase LDH lactate dehydrogenase LHRH luteinizing hormone-releasing hormone MDA malonaldehyde NHS N-hydroxy succinimide NLG N-lauryl glucosamine NTAR DoxNio non-targeted doxorubicin niosomes PBS phosphate buffer saline RGD argynyl glycyl aspartic acid SGOT serum glutamate oxaloacetate transaminase SGPT serum glutamate pyruvate transaminase SOD superoxide dismutase TAR DoxNio targeted doxorubicin niosomes Vd volume of distribution.
Collapse
Affiliation(s)
- Smita Pawar
- a Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology , Elite Status and Center of Excellence - Govt. of Maharashtra , Mumbai , Maharashtra , India
| | - Ganesh Shevalkar
- a Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology , Elite Status and Center of Excellence - Govt. of Maharashtra , Mumbai , Maharashtra , India
| | - Pradeep Vavia
- a Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology , Elite Status and Center of Excellence - Govt. of Maharashtra , Mumbai , Maharashtra , India
| |
Collapse
|
9
|
Kim N, Kwak SH, Lee SH, Juvekar V, Lee BI, Ahn HC, Kim SY, Gong YD. Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors. Org Biomol Chem 2015; 12:4932-40. [PMID: 24879506 DOI: 10.1039/c4ob00179f] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
In the process of optimization, we developed a novel core skeleton of thieno[3,4-b]pyrazine via GK-13. The derivatives synthesized were shown to inhibit TGase 2 activity in cancer cells. Some of the hit compounds such as the arylethynyl group-coupled thieno[3,4-b]pyrazine derivatives were shown to exhibit promising activity for use as potential therapeutic small-molecules in renal cancer by inhibiting TGase 2 activity.
Collapse
Affiliation(s)
- Nayeon Kim
- Innovative Drug Library Research Center, Dongguk University, Seoul, 100-715, Republic of Korea.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Huang YC, Wei KC, Chang CN, Chen PY, Hsu PW, Chen CP, Lu CS, Wang HL, Gutmann DH, Yeh TH. Transglutaminase 2 expression is increased as a function of malignancy grade and negatively regulates cell growth in meningioma. PLoS One 2014; 9:e108228. [PMID: 25247996 PMCID: PMC4172767 DOI: 10.1371/journal.pone.0108228] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2014] [Accepted: 08/26/2014] [Indexed: 02/01/2023] Open
Abstract
Most meningiomas are benign, but some clinical-aggressive tumors exhibit brain invasion and cannot be resected without significant complications. To identify molecular markers for these clinically-aggressive meningiomas, we performed microarray analyses on 24 primary cultures from 21 meningiomas and 3 arachnoid membranes. Using this approach, increased transglutaminase 2 (TGM2) expression was observed, which was subsequently validated in an independent set of 82 meningiomas by immunohistochemistry. Importantly, the TGM2 expression level was associated with increasing WHO malignancy grade as well as meningioma recurrence. Inhibition of TGM2 function by siRNA or cystamine induced meningioma cell death, which was associated with reduced AKT phosphorylation and caspase-3 activation. Collectively, these findings suggest that TGM2 expression increases as a function of malignancy grade and tumor recurrence and that inhibition of TGM2 reduces meningioma cell growth.
Collapse
Affiliation(s)
- Yin-Cheng Huang
- Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
- Chang Gung University, College of Medicine, Taoyuan, Taiwan
| | - Kuo-Chen Wei
- Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
- Chang Gung University, College of Medicine, Taoyuan, Taiwan
| | - Chen-Nen Chang
- Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
- Chang Gung University, College of Medicine, Taoyuan, Taiwan
| | - Pin-Yuan Chen
- Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
- Chang Gung University, College of Medicine, Taoyuan, Taiwan
| | - Peng-Wei Hsu
- Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
- Chang Gung University, College of Medicine, Taoyuan, Taiwan
| | - Carl P. Chen
- Department of Rehabilitation, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
- Chang Gung University, College of Medicine, Taoyuan, Taiwan
| | - Chin-Song Lu
- Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
- Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
- Chang Gung University, College of Medicine, Taoyuan, Taiwan
| | - Hung-Li Wang
- Chang Gung University, College of Medicine, Taoyuan, Taiwan
| | - David H. Gutmann
- Department of Neurology, Washington University, School of Medicine, St. Louis, Missouri, United States of America
| | - Tu-Hsueh Yeh
- Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
- Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
- Chang Gung University, College of Medicine, Taoyuan, Taiwan
- * E-mail:
| |
Collapse
|
11
|
Jin SY, Lim WS, Sung NH, Cheong KA, Lee AY. Combination of glucosamine and low-dose cyclosporine for atopic dermatitis treatment: A randomized, placebo-controlled, double-blind, parallel clinical trial. Dermatol Ther 2014; 28:44-51. [DOI: 10.1111/dth.12163] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Sang-Yoon Jin
- Department of Dermatology; Dongguk University Ilsan Hospital; Dongguk University Graduate School of Medicine; Gyeonggi-do South Korea
| | - Won-Suk Lim
- Department of Dermatology; Dongguk University Ilsan Hospital; Dongguk University Graduate School of Medicine; Gyeonggi-do South Korea
| | - Nam Hee Sung
- Department of Dermatology; Dongguk University Ilsan Hospital; Dongguk University Graduate School of Medicine; Gyeonggi-do South Korea
| | - Kyung Ah Cheong
- Department of Dermatology; Dongguk University Ilsan Hospital; Dongguk University Graduate School of Medicine; Gyeonggi-do South Korea
| | - Ai-Young Lee
- Department of Dermatology; Dongguk University Ilsan Hospital; Dongguk University Graduate School of Medicine; Gyeonggi-do South Korea
| |
Collapse
|
12
|
Weimer S, Priebs J, Kuhlow D, Groth M, Priebe S, Mansfeld J, Merry TL, Dubuis S, Laube B, Pfeiffer AF, Schulz TJ, Guthke R, Platzer M, Zamboni N, Zarse K, Ristow M. D-Glucosamine supplementation extends life span of nematodes and of ageing mice. Nat Commun 2014; 5:3563. [PMID: 24714520 PMCID: PMC3988823 DOI: 10.1038/ncomms4563] [Citation(s) in RCA: 154] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2014] [Accepted: 03/05/2014] [Indexed: 12/28/2022] Open
Abstract
D-Glucosamine (GlcN) is a freely available and commonly used dietary supplement potentially promoting cartilage health in humans, which also acts as an inhibitor of glycolysis. Here we show that GlcN, independent of the hexosamine pathway, extends Caenorhabditis elegans life span by impairing glucose metabolism that activates AMP-activated protein kinase (AMPK/AAK-2) and increases mitochondrial biogenesis. Consistent with the concept of mitohormesis, GlcN promotes increased formation of mitochondrial reactive oxygen species (ROS) culminating in increased expression of the nematodal amino acid-transporter 1 (aat-1) gene. Ameliorating mitochondrial ROS formation or impairment of aat-1-expression abolishes GlcN-mediated life span extension in an NRF2/SKN-1-dependent fashion. Unlike other calorie restriction mimetics, such as 2-deoxyglucose, GlcN extends life span of ageing C57BL/6 mice, which show an induction of mitochondrial biogenesis, lowered blood glucose levels, enhanced expression of several murine amino-acid transporters, as well as increased amino-acid catabolism. Taken together, we provide evidence that GlcN extends life span in evolutionary distinct species by mimicking a low-carbohydrate diet.
Collapse
Affiliation(s)
- Sandra Weimer
- Energy Metabolism Laboratory, ETH Zürich (Swiss Federal Institute of Technology Zurich), Zürich CH-8603, Switzerland
- German Institute of Human Nutrition Potsdam-Rehbrücke, D-14558 Nuthetal, Germany
- These authors contributed equally to the work
| | - Josephine Priebs
- Department of Human Nutrition, Institute of Nutrition, University of Jena, D-07743 Jena, Germany
- These authors contributed equally to the work
| | - Doreen Kuhlow
- German Institute of Human Nutrition Potsdam-Rehbrücke, D-14558 Nuthetal, Germany
- Department of Human Nutrition, Institute of Nutrition, University of Jena, D-07743 Jena, Germany
| | - Marco Groth
- Genome Analysis Group, Leibniz Institute for Age Research, Fritz-Lipmann-Institute, D-07745 Jena, Germany
| | - Steffen Priebe
- Systems Biology and Bioinformatics Group, Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knöll-Institute, D-07745 Jena, Germany
| | - Johannes Mansfeld
- Energy Metabolism Laboratory, ETH Zürich (Swiss Federal Institute of Technology Zurich), Zürich CH-8603, Switzerland
- Department of Human Nutrition, Institute of Nutrition, University of Jena, D-07743 Jena, Germany
- DFG Graduate School of Adaptive Stress Response #1715, D-07745 Jena, Germany
| | - Troy L. Merry
- Energy Metabolism Laboratory, ETH Zürich (Swiss Federal Institute of Technology Zurich), Zürich CH-8603, Switzerland
| | - Sébastien Dubuis
- Institute of Molecular Systems Biology, ETH Zürich (Swiss Federal Institute of Technology Zurich), Zürich CH-8093, Switzerland
| | - Beate Laube
- Energy Metabolism Laboratory, ETH Zürich (Swiss Federal Institute of Technology Zurich), Zürich CH-8603, Switzerland
- Department of Human Nutrition, Institute of Nutrition, University of Jena, D-07743 Jena, Germany
| | - Andreas F. Pfeiffer
- German Institute of Human Nutrition Potsdam-Rehbrücke, D-14558 Nuthetal, Germany
| | - Tim J. Schulz
- German Institute of Human Nutrition Potsdam-Rehbrücke, D-14558 Nuthetal, Germany
| | - Reinhard Guthke
- Systems Biology and Bioinformatics Group, Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knöll-Institute, D-07745 Jena, Germany
| | - Matthias Platzer
- Genome Analysis Group, Leibniz Institute for Age Research, Fritz-Lipmann-Institute, D-07745 Jena, Germany
| | - Nicola Zamboni
- Institute of Molecular Systems Biology, ETH Zürich (Swiss Federal Institute of Technology Zurich), Zürich CH-8093, Switzerland
| | - Kim Zarse
- Energy Metabolism Laboratory, ETH Zürich (Swiss Federal Institute of Technology Zurich), Zürich CH-8603, Switzerland
- Department of Human Nutrition, Institute of Nutrition, University of Jena, D-07743 Jena, Germany
| | - Michael Ristow
- Energy Metabolism Laboratory, ETH Zürich (Swiss Federal Institute of Technology Zurich), Zürich CH-8603, Switzerland
- German Institute of Human Nutrition Potsdam-Rehbrücke, D-14558 Nuthetal, Germany
- Department of Human Nutrition, Institute of Nutrition, University of Jena, D-07743 Jena, Germany
| |
Collapse
|
13
|
The novel IGF-IR/Akt-dependent anticancer activities of glucosamine. BMC Cancer 2014; 14:31. [PMID: 24438088 PMCID: PMC3901559 DOI: 10.1186/1471-2407-14-31] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2013] [Accepted: 01/15/2014] [Indexed: 11/13/2022] Open
Abstract
Background Recent studies have shown that glucosamine inhibits the proliferation of various human cancer cell lines and downregulates the activity of COX-2, HIF-1α, p70S6K, and transglutaminase 2. Because the IGF-1R/Akt pathway is a common upstream regulator of p70S6K, HIF-1α, and COX-2, we hypothesized that glucosamine inhibits cancer cell proliferation through this pathway. Methods We used various in vitro assays including flow cytometry assays, small interfering RNA (siRNA) transfection, western blot analysis, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays, reverse transcription-polymerase chain reaction, and in vivo xenograft mouse model to confirm anticancer activities of glucosamine and to investigate the molecular mechanism. Results We found that glucosamine inhibited the growth of human non-small cell lung cancer (NSCLC) cells and negatively regulated the expression of IGF-1R and phosphorylation of Akt. Glucosamine decreased the stability of IGF-1R and induced its proteasomal degradation by increasing the levels of abnormal glycosylation on IGF-1R. Moreover, picropodophyllin, a selective inhibitor of IGF-1R, and the IGF-1R blocking antibody IMC-A12 induced significant cell growth inhibition in glucosamine-sensitive, but not glucosamine-resistant cell lines. Using in vivo xenograft model, we confirmed that glucosamine prohibits primary tumor growth through reducing IGF-1R signalling and increasing ER-stress. Conclusions Taken together, our results suggest that targeting the IGF-1R/Akt pathway with glucosamine may be an effective therapeutic strategy for treating some type of cancer.
Collapse
|
14
|
Boyère C, Duhem N, Debuigne A, Préat V, Jérôme C, Riva R. Elaboration of drug nanocarriers based on a glucosamine labeled amphiphilic polymer. Polym Chem 2014. [DOI: 10.1039/c3py01730c] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
A new amphiphilic polymer was successfully synthesized using a metal free synthetic strategy for the elaboration of glucosamine labeled drug carriers.
Collapse
Affiliation(s)
- C. Boyère
- University of Liège
- Center for Education and Research on Macromolecules (CERM)
- Chemistry Department
- 4000 Liège
- Belgium
| | - N. Duhem
- Université Catholique de Louvain
- Louvain Drug Research Institute (LDRI)
- Unit of Pharmaceutics
- 1200 Brussels
- Belgium
| | - A. Debuigne
- University of Liège
- Center for Education and Research on Macromolecules (CERM)
- Chemistry Department
- 4000 Liège
- Belgium
| | - V. Préat
- Université Catholique de Louvain
- Louvain Drug Research Institute (LDRI)
- Unit of Pharmaceutics
- 1200 Brussels
- Belgium
| | - C. Jérôme
- University of Liège
- Center for Education and Research on Macromolecules (CERM)
- Chemistry Department
- 4000 Liège
- Belgium
| | - R. Riva
- University of Liège
- Center for Education and Research on Macromolecules (CERM)
- Chemistry Department
- 4000 Liège
- Belgium
| |
Collapse
|
15
|
Park MK, Cho SA, Lee HJ, Lee EJ, Kang JH, Kim YL, Kim HJ, Oh SH, Choi C, Lee H, Kim SY. Suppression of Transglutaminase-2 is Involved in Anti-Inflammatory Actions of Glucosamine in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Skin Inflammation. Biomol Ther (Seoul) 2013; 20:380-5. [PMID: 24009824 PMCID: PMC3762271 DOI: 10.4062/biomolther.2012.20.4.380] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2012] [Revised: 07/06/2012] [Accepted: 07/10/2012] [Indexed: 01/21/2023] Open
Abstract
Glucosamine (GS) is well known for the treatment of inflam-mation. However, the mechanism and efficacy of GS for skin inflammation are unclear. The aim of this study was to evaluate the effects and mechanism of GS in the mouse 12-O-tetradecanoyl 13-acetate (TPA)-induced ear edema model. TPA-induced ear edema was evoked in ICR or transglutaminase 2 (Tgase-2) (-/-) mice. GS was administered orally (10-100 mg/kg) or topically (0.5-2.0 w/v %) prior to TPA treatment. Orally administered GS at 10 mg/kg showed a 76 or 57% reduction in ear weight or myeloperoxidase, respectively, and a decreased expression of cyclooxy-genase-2 (COX-2), NF-κB and Tgase-2 in TPA-induced ear edema by western blot and immunohistochemistry. Role of Tgase-2 in TPA ear edema is examined using Tgase-2 (-/-) mice and TPA did not induce COX-2 expression in ear of Tgase-2 (-/-) mice. These observations suggested that Tgase-2 is involved in TPA-induced COX-2 expression in the inflamed ear of mice and anti-inflammatory effects of glucosamine is mediated through suppression of Tgase-2 in TPA ear edema.
Collapse
Affiliation(s)
- Mi Kyung Park
- College of Pharmacy, Dongguk University, Goyang 410-820, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor. J Cancer Res Clin Oncol 2013; 139:1279-94. [PMID: 23604466 DOI: 10.1007/s00432-013-1433-1] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2013] [Accepted: 03/27/2013] [Indexed: 12/26/2022]
Abstract
PURPOSE Transglutaminase 2 (TGase 2), a cross-linking enzyme, plays an important role in both pro-survival and anti-apoptosis during oncogenesis. For instance, TGase 2 induces NF-κB activation through I-κBα polymerization, which leads to the increase of pro-survival factors such as BCl-2. TGase 2 also suppresses apoptosis via depletion of caspase 3 and cathepsin D. Therefore, a specific TGase 2 inhibitor may become a very useful treatment for cancer showing high levels of TGase 2 expression. METHODS By small-molecule library screening, we managed to locate a competitive TGase 2 inhibiting quinoxaline compound (GK13) from 50 other quinoxaline derivatives. The 50 compounds that were screened represent a thousand structurally diverse, potentially pharmaceutical heterocyclic compound libraries, including benzopyrans, oxadiazoles, thiadiazoles, and quinoxalines. By measuring GI50, TGI, and LC50 using SRB assay, GK13 was selected. RESULTS In vitro enzyme kinetics using guinea pig liver TGase 2 showed that IC50 value was about 16.4 E-6 M. GK13 inhibits TGase 2-mediated I-κBα polymerization in a dose-dependent manner. LC50 of GK13 showed greater efficacy as 4.3E-4 M than LC50 of doxorubicin that showed efficacy as 3.87E-3 M in NCC72 composing 11 tissue origins and 72 cancer cell lines. CONCLUSION GK13 showed a possibility that quinoxaline derivatives may be effective for anti-cancer activity via TGase 2 inhibition.
Collapse
|
17
|
KWON HB, AHN BJ, CHOI Y, JIN SY, CHEONG KA, LEE J, LEE AY. Combination of glucosamine improved therapeutic effect of low-dose cyclosporin A in patients with atopic dermatitis: A pilot study. J Dermatol 2013; 40:207-10. [DOI: 10.1111/1346-8138.12003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2012] [Accepted: 08/24/2012] [Indexed: 12/01/2022]
Affiliation(s)
- Hyok-Bu KWON
- Department of Dermatology; Dongguk University Seoul; Graduate School of Medicine; Goyang-si
| | - Byung-Jin AHN
- Department of Medicine; Graduate School; Dongguk University
| | - Yunseok CHOI
- Department of Dermatology; Dongguk University Seoul; Graduate School of Medicine; Goyang-si
| | - Sang Y. JIN
- Department of Dermatology; Dongguk University Seoul; Graduate School of Medicine; Goyang-si
| | - Kyung A. CHEONG
- Department of Dermatology; Dongguk University Seoul; Graduate School of Medicine; Goyang-si
| | - Joongyub LEE
- Medical Research Collaborating Center; Seoul National University Hospital; Seoul; South Korea
| | - Ai-Young LEE
- Department of Dermatology; Dongguk University Seoul; Graduate School of Medicine; Goyang-si
| |
Collapse
|
18
|
Jin T, Lin HX, Lin H, Guo LB, Ge N, Cai XY, Sun R, Chen WK, Li QL, Hu WH. Expression TGM2 and BNIP3 have prognostic significance in laryngeal cancer patients receiving surgery and postoperative radiotherapy: a retrospective study. J Transl Med 2012; 10:64. [PMID: 22458929 PMCID: PMC3362769 DOI: 10.1186/1479-5876-10-64] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2011] [Accepted: 03/30/2012] [Indexed: 12/26/2022] Open
Abstract
Background This study was designed to determine the pattern and correlation between expression of the HIF-1α transcriptional targets TGM2 and BNIP3 in laryngeal cancer, and investigate the association of BNIP3 and TGM2 with clinical outcome in laryngeal squamous cell carcinoma (SCC) patients receiving postoperative radiotherapy. Methods Immunostaining with antibodies specific to BNIP3 and TGM2 was performed in formalin-fixed, paraffin-embedded specimens from 148 laryngeal SCC patients. BNIP3 and TGM2 expression was scored as high or low, based on the number of tumor cells stained and the staining intensity. All patients received postoperative radiotherapy. Patient follow up and clinicopathological data were compared using the Chi-squared test, univariate and multivariate analyses, and survival curves were generated using the Kaplan-Meier method and log-rank test. Results The 3, 5 and 10-year overall survival rates (OS) for all patients were 77.7%, 71.6%, 56.4%, respectively. Primary tumor site, T stage, overall stage, lymph-node metastasis, BNIP3 expression and TGM2 expression were significant prognostic factors for OS in univariate analysis. Negative cervical lymph nodes, high BNIP3 expression and low TGM2 expression were independent prognostic factors of improved OS in multivariate analysis. BNIP3 expression correlates with TGM2 expression in laryngeal SCC (P = 0.012). Conclusions This study indicates that lymph-node metastasis, BNIP3 expression and TGM2 expression are independent prognostic factors in laryngeal SCC patients receiving postoperative radiotherapy. Further studies are required to investigate how BNIP3 and/or TGM2 influence the prognosis of laryngeal SCC patients treated with postoperative radiotherapy, and to determine how TGM2 and BNIP3 expression are regulated.
Collapse
Affiliation(s)
- Ting Jin
- Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications. Pharmacol Ther 2011; 133:392-410. [PMID: 22212614 DOI: 10.1016/j.pharmthera.2011.12.003] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2011] [Accepted: 12/06/2011] [Indexed: 12/24/2022]
Abstract
Neurodegenerative disorders are characterized by progressive neuronal loss and the aggregation of disease-specific pathogenic proteins in hallmark neuropathologic lesions. Many of these proteins, including amyloid Αβ, tau, α-synuclein and huntingtin, are cross-linked by the enzymatic activity of transglutaminase 2 (TG2). Additionally, the expression and activity of TG2 is increased in affected brain regions in these disorders. These observations along with experimental evidence in cellular and mouse models suggest that TG2 can contribute to the abnormal aggregation of disease causing proteins and consequently to neuronal damage. This accumulating evidence has provided the impetus to develop inhibitors of TG2 as possible neuroprotective agents. However, TG2 has other enzymatic activities in addition to its cross-linking function and can modulate multiple cellular processes including apoptosis, autophagy, energy production, synaptic function, signal transduction and transcription regulation. These diverse properties must be taken into consideration in designing TG2 inhibitors. In this review, we discuss the biochemistry of TG2, its various physiologic functions and our current understanding about its role in degenerative diseases of the brain. We also describe the different approaches to designing TG2 inhibitors that could be developed as potential disease-modifying therapies.
Collapse
|
20
|
Transglutaminase 2 as a biomarker of osteoarthritis: an update. Amino Acids 2011; 44:199-207. [PMID: 22139411 DOI: 10.1007/s00726-011-1181-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2011] [Accepted: 11/22/2011] [Indexed: 01/05/2023]
Abstract
Osteoarthritis is a progressive joint disease characterized by cartilage degradation and bone remodelling. Under physiologic conditions, articular cartilage displays a stable chondrocyte phenotype, whereas in osteoarthritis a chondrocyte hypertrophy develops near the sites of cartilage surface damage and associates to the pathologic expression of type X collagen. Transglutaminases (TGs) include a family of Ca(2+)-dependent enzymes that catalyze the formation of γ-glutamyl cross-links. Their substrates include a variety of intracellular and extracellular macromolecular components. TGs are ubiquitously and abundantly expressed and implicated in a variety of physiopathological processes. TGs activity is modulated by inflammatory cytokines. TG2 (also known as tissue transglutaminase) mediates the hypertrophic differentiation of joint chondrocytes and interleukin-1-induced calcification. Histomorphometrical and biomolecular investigations document increased TG2 expression in human and experimental osteoarthritis. Consequently, the level of TG2 expression may represent an adjuvant additional marker to monitor tissue remodelling occurring in osteoarthritic joint tissue. Experimental induction of osteoarthritis in TG2 knockout mice is followed from reduced cartilage destruction and increased osteophyte formation compared to wild-type mice, suggesting a different influence on joint bone and cartilage remodelling. The capacity of transamidation by TG2 to regulate activation of latent TGF-β seems to have a potential impact on the regulation of inflammatory response in osteoarthritic tissues. Additional studies are needed to define TG2-regulated pathways that are differently modulated in osteoblasts and chondrocytes during osteoarthritis.
Collapse
|
21
|
Hoffner G, Vanhoutteghem A, André W, Djian P. Transglutaminase in epidermis and neurological disease or what makes a good cross-linking substrate. ADVANCES IN ENZYMOLOGY AND RELATED AREAS OF MOLECULAR BIOLOGY 2011; 78:97-160. [PMID: 22220473 DOI: 10.1002/9781118105771.ch3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Guylaine Hoffner
- Unité Propre de Recherche 2228 du Centre National de la Recherche Scientifique, Régulation de la Transcription et Maladies Génétiques, Université Paris Descartes, Paris, France
| | | | | | | |
Collapse
|
22
|
Kim SY. Transglutaminase 2: a new paradigm for NF-kappaB involvement in disease. ADVANCES IN ENZYMOLOGY AND RELATED AREAS OF MOLECULAR BIOLOGY 2011; 78:161-95. [PMID: 22220474 DOI: 10.1002/9781118105771.ch4] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Soo-Youl Kim
- Division of Cancer Biology, Research Institute, National Cancer Center, Kyonggi-do, Republic of Korea
| |
Collapse
|
23
|
Kang JH, Song KH, Jeong KC, Kim S, Choi C, Lee CH, Oh SH. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer 2011; 11:334. [PMID: 21813027 PMCID: PMC3199868 DOI: 10.1186/1471-2407-11-334] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2011] [Accepted: 08/04/2011] [Indexed: 02/07/2023] Open
Abstract
Background A major problem with the use of current chemotherapy regimens for several cancers, including breast cancer, is development of intrinsic or acquired drug resistance, which results in disease recurrence and metastasis. However, the mechanisms underlying this drug resistance are unknown. To study the molecular mechanisms underlying the invasive and metastatic activities of drug-resistant cancer cells, we generated a doxorubicin-resistant MCF-7 breast cancer cell line (MCF-7/DOX). Methods We used MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays, flow cytometry assays, DNA fragmentation assays, Western blot analysis, cell invasion assays, small interfering RNA (siRNA) transfection, reverse transcription-polymerase chain reaction, experimental lung metastasis models, and gelatin and fibrinogen/plasminogen zymography to study the molecular mechanism of metastatic activities in MCF-7/DOX cells. Results We found that MCF-7/DOX acquired invasive activities. In addition, Western blot analysis showed increased expression of epidermal growth factor receptor (EGFR) and Cox-2 in MCF-7/DOX cells. Inhibition of Cox-2, phosphoinositide 3-kinase (PI3K)/Akt, or mitogen-activated protein kinase (MAPK) pathways effectively inhibited the invasive activities of MCF-7/DOX cells. Gelatin and fibrinogen/plasminogen zymography analysis showed that the enzymatic activities of matrix metalloproteinase-2 (MMP-2), MMP-9, and urokinase-type plasminogen activator were markedly higher in MCF-7/DOX cells than in the MCF-7 cells. In vitro invasion assays and mouse models of lung metastasis demonstrated that MCF-7/DOX cells acquired invasive abilities. Using siRNAs and agonists specific for prostaglandin E (EP) receptors, we found that EP1 and EP3 played important roles in the invasiveness of MCF-7/DOX cells. Conclusions We found that the invasive activity of MCF-7/DOX cells is mediated by Cox-2, which is induced by the EGFR-activated PI3K/Akt and MAPK pathways. In addition, EP1 and EP3 are important in the Cox-2-induced invasion of MCF-7/DOX cells. Therefore, not only Cox-2 but also EP1 and EP3 could be important targets for chemosensitization and inhibition of metastasis in breast cancers that are resistant to chemotherapy.
Collapse
Affiliation(s)
- Ju-Hee Kang
- Division of Cancer Biology, National Cancer Center, Ilsan-ro 323, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769, Republic of Korea
| | | | | | | | | | | | | |
Collapse
|
24
|
Jeong KC, Ahn KO, Lee BI, Lee CH, Kim SY. The mechanism of transglutaminase 2 inhibition with glucosamine: implications of a possible anti-inflammatory effect through transglutaminase inhibition. J Cancer Res Clin Oncol 2011; 136:143-50. [PMID: 19655169 DOI: 10.1007/s00432-009-0645-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2009] [Accepted: 07/17/2009] [Indexed: 11/30/2022]
Abstract
PURPOSE Although many efforts on revealing mechanism of the constitutive activation of NF-κB in cancer cells contributed to understanding canonical pathways, largely it remains to be determined for therapeutic approaches. Recently, we found that increased expression of transglutaminase 2 (TGase 2) appears to be responsible for constitutive activation of NF-κB in certain types of cancer cells. In previous studies, we demonstrated that TGase 2 inhibition markedly increases anti-cancer drug sensitivity in drug resistance cancer cells. Therefore, we develop safe and effective TGase 2 inhibitors for therapeutic approach. METHODS We screened a chemical library of natural compounds using in vitro TGase 2 activity assay. The salient discovery was that glucosamine (GlcN), a known anti-inflammatory substance, inhibited the cross-linking activity of TGase 2. We tested, through a biochemical analysis including kinetics, whether the GlcN and GlcN analogs specifically inhibit TGase 2. We also determined the inhibitory mechanism using conformational change of TGase 2. RESULTS We found that the primary amine of GlcN plays a key role in TGase 2 inhibition. We also demonstrated that GlcN reversed TGase 2-mediated I-κBα polymerization in vitro. Interestingly, the metabolite of GlcN, glucosamine-6-phosphate (GlcN6P), inhibited TGase 2 activity via binding to the GTP-binding site with better efficiency than GlcN. In the native gel electrophoresis, it was clearly observed that GlcN6P binds to TGase 2 directly as an allosteric inhibitor. CONCLUSIONS We concluded that GlcN inhibits TGase 2 activity by direct contact. GlcN and its metabolite GlcN6P can down-regulate constitutive activation of NF-κB in vivo via inhibition of TGase 2.
Collapse
Affiliation(s)
- Kyung-Chae Jeong
- Cancer Cell and Molecular Biology Branch, Division of Cancer Biology, Research Institute, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do, 410-769, Republic of Korea
| | | | | | | | | |
Collapse
|
25
|
Veerapandian M, Lim SK, Nam HM, Kuppannan G, Yun KS. Glucosamine-functionalized silver glyconanoparticles: characterization and antibacterial activity. Anal Bioanal Chem 2010; 398:867-76. [DOI: 10.1007/s00216-010-3964-5] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2010] [Revised: 06/10/2010] [Accepted: 06/22/2010] [Indexed: 01/05/2023]
|
26
|
Park KS, Kim HK, Lee JH, Choi YB, Park SY, Yang SH, Kim SY, Hong KM. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol 2009; 136:493-502. [PMID: 19763620 DOI: 10.1007/s00432-009-0681-6] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2009] [Accepted: 09/02/2009] [Indexed: 01/06/2023]
Abstract
PURPOSE Recently, it was reported that expression of transglutaminase 2 plays an important role in doxorubicin/cisplatin resistance in breast and ovarian cancer. The aims of this study were to verify the role of transglutaminase 2 in cisplatin response in non-small cell lung cancer (NSCLC) and to study if transglutaminase 2 gene (TGM2) methylation can be a molecular marker for good response to cisplatin. METHODS TGM2 promoter methylation was analyzed by sodium bisulfite sequencing. Cisplatin sensitivity was analyzed by treatment of cisplatin in NSCLC cell lines with/without TGM2 or TGM2 siRNA transfection. RESULTS In one-third of NSCLC cell lines, TGase 2 gene (TGM2) was silenced by promoter methylation. The TGM2 promoter-methylated cell lines (HCC-95 and HCC-1588) showed relatively higher sensitivity to cisplatin than the TGM2-expressing cell lines (NCI-H1299 and HCC-1195). Down-regulation and over-expression of TGM2 in those NSCLC cells also suggested a positive correlation of cisplatin sensitivity and TGM2 inhibition. With doxorubicin, the relationship was quite similar. CONCLUSIONS We showed that good responders of cisplatin in NSCLC could be identified by the promoter methylation of TGM2 and that TGase 2 inhibition appears to be an effective cisplatin-sensitizing modality in NSCLC.
Collapse
Affiliation(s)
- Kang-Seo Park
- Research Institute, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang, 410-769, Korea
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Chesnokov V, Sun C, Itakura K. Glucosamine suppresses proliferation of human prostate carcinoma DU145 cells through inhibition of STAT3 signaling. Cancer Cell Int 2009; 9:25. [PMID: 19744341 PMCID: PMC2747838 DOI: 10.1186/1475-2867-9-25] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2009] [Accepted: 09/10/2009] [Indexed: 11/10/2022] Open
Abstract
Background Glucosamine is known as a toxic agent for several malignant cell lines and transplanted tumors with little toxicity to normal host tissues. However, the mechanisms underlying anticancer activity of glucosamine are poorly understood. To study the mechanisms, the human prostate cancer DU145 cells were used for the model. Results Glucosamine at concentration 2 mM suppressed proliferation and induced death of DU145 cells. Detailed analysis showed that glucosamine decreased DNA synthesis, arrested cell cycle at G1 phase and induced apoptosis. The effects of glucosamine were associated with up-regulation of p21waf1/cip, a CDK inhibitor. Our further studies identified glucosamine as an inhibitor of signal transducer and activator of transcription (STAT) 3 which is constitutively activated in many cancer cells including DU145 cells. Glucosamine inhibited phosphorylation of STAT3 at the Tyr705 residue and as a result, reduced STAT3 DNA binding and transcriptional activities. Indeed, the expression of apoptosis inhibitor survivin, which is well known target of STAT3, was suppressed. Contrary to DU145 cells, glucosamine did not affect proliferation of other human prostate cancer PC-3 and C4-2B cells, in which STAT 3 signal pathway is not constitutively active. Conclusion Our data identifies glucosamine as a suppressor of STAT3 signaling and suggests that anticancer activity of glucosamine may be attributed to the suppression of STAT3 activity. Potential application of glucosamine for the treatment of tumors with constitutively active STAT3 is proposed.
Collapse
Affiliation(s)
- Viktor Chesnokov
- Department of Molecular Biology, Beckman Research Institute of the City of Hope, 1450 East Duarte road, Duarte, California 91010, USA.
| | | | | |
Collapse
|
28
|
Kim DE, Kim JY, Schellingerhout D, Shon SM, Jeong SW, Kim EJ, Kim WK. Molecular Imaging of Cathepsin B Proteolytic Enzyme Activity Reflects the Inflammatory Component of Atherosclerotic Pathology and Can Quantitatively Demonstrate the Antiatherosclerotic Therapeutic Effects of Atorvastatin and Glucosamine. Mol Imaging 2009. [DOI: 10.2310/7290.2009.00027] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Inflammation in atherosclerotic plaques causes plaque vulnerability and rupture, leading to thromboembolic complications. Cathepsin B (CatB) proteases secreted by macrophages play a major role in plaque inflammation. We used a CatB-activatable near-infrared fluorescence (NIRF) imaging agent to demonstrate the inflammatory component in mice atheromata and the atherosclerosis-modulating effects of atorvastatin or glucosamine treatments. Apolipoprotein E knockout mice ( n = 35) were fed normal chow, a Western diet, a Western diet + atorvastatin, a Western diet + glucosamine, or a Western diet + atorvastatin + glucosamine for 14 weeks. Twenty-four hours after the intravenous injection of a CatB-activatable probe, ex vivo NIRF imaging of the aortas and brains was performed, followed by histology. The CatB-related signal, observed in the aortas but not in the cerebral arteries, correlated very well with protease activity and the presence of macrophages on histology. Animals on Western diets could be distinguished from animals on a normal diet. The antiatherosclerotic effects of atorvastatin and glucosamine could be demonstrated, with reduced CatB-related signal compared with untreated animals. Plaque populations were heterogeneous within individuals, with some plaques showing a high and others a lower CatB-related signal. These differences in signal intensity could not be predicted by visual inspection of the plaques but did correlate with histologic evidence of inflammation in every case. This suggests that vulnerable inflamed plaques can be identified by optical molecular imaging.
Collapse
Affiliation(s)
- Dong-Eog Kim
- From the Molecular Imaging and Neurovascular Research Laboratory, Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Republic of Korea, and Departments of Radiology and Experimental Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX
| | - Jeong-Yeon Kim
- From the Molecular Imaging and Neurovascular Research Laboratory, Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Republic of Korea, and Departments of Radiology and Experimental Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX
| | - Dawid Schellingerhout
- From the Molecular Imaging and Neurovascular Research Laboratory, Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Republic of Korea, and Departments of Radiology and Experimental Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX
| | - Soo-Min Shon
- From the Molecular Imaging and Neurovascular Research Laboratory, Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Republic of Korea, and Departments of Radiology and Experimental Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX
| | - Sang-Wuk Jeong
- From the Molecular Imaging and Neurovascular Research Laboratory, Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Republic of Korea, and Departments of Radiology and Experimental Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX
| | - Eo-Jin Kim
- From the Molecular Imaging and Neurovascular Research Laboratory, Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Republic of Korea, and Departments of Radiology and Experimental Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX
| | - Woo Kyung Kim
- From the Molecular Imaging and Neurovascular Research Laboratory, Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Republic of Korea, and Departments of Radiology and Experimental Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
29
|
Huebner JL, Johnson KA, Kraus VB, Terkeltaub RA. Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA. Osteoarthritis Cartilage 2009; 17:1056-64. [PMID: 19328881 PMCID: PMC3249463 DOI: 10.1016/j.joca.2009.02.015] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2008] [Revised: 01/29/2009] [Accepted: 02/11/2009] [Indexed: 02/02/2023]
Abstract
OBJECTIVE The transglutaminase (TG) isoenzyme TG2, which catalyzes protein cross-linking via transamidation, influences healing phenotype in multiple forms of tissue injury. Moreover, TG2 knockout suppresses cartilage destruction but promotes osteophyte formation in instability-induced mouse knee osteoarthritis (OA). TG2 is marker of growth plate chondrocyte hypertrophy. Moreover, TG2 secreted by chondrocytes acts in part by promoting chondrocyte maturation to hypertrophy, a differentiation state linked with MMP-13 expression and disease progression in OA. Moreover, glucosamine, which is currently under investigation as an OA therapy, binds and inhibits TG2. Here, we examined TG2 as a potential marker of cartilage hypertrophy in the spontaneous guinea pig model of OA. METHODS Synovial fluid ELISA and cartilage Immunohistochemistry and quantitative Reverse transcription-polymerase chain reaction (RT-PCR), were used to examine TG2 expression and TG transamidation-catalyzed isopeptide bonds. RESULTS TG isopeptide bonds and TG2 were most abundant in articular cartilage in early knee OA. TG2 expression was robust at sites of early but not established osteophytes. Synovial fluid TG2 correlated with knee OA total histological score (r=0.47, P=0.01), as did medial tibial plateau cartilage TG2 mRNA (r=1.0, P=0.003). At 12 months of age, medial tibial plateau cartilage TG2 mRNA expression rose markedly in association with elevated type X collagen, as well as ADAMTS-5, and MMP-13 expression, changes not shared in age-matched Strain 13 guinea pigs that are less susceptible to knee OA. CONCLUSION Hartley guinea pig knee TG2 expression associates with enhanced articular chondrocyte hypertrophy and is a biomarker of OA severity.
Collapse
Affiliation(s)
- Janet L Huebner
- Department of Medicine, Division of Rheumatology, Duke University Medical Center, Durham, NC 27710
| | | | - Virginia B. Kraus
- Department of Medicine, Division of Rheumatology, Duke University Medical Center, Durham, NC 27710
| | | |
Collapse
|
30
|
|